LAWRENCEVILLE, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that...
Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in overall survival (OS) in the intent-to-treat...
Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.375 | 0.3845 | 0.375 | 60624 | 0.375 | DE |
4 | 0 | 0 | 0.375 | 0.3999 | 0.325 | 176352 | 0.375 | DE |
12 | 0 | 0 | 0.375 | 0.425 | 0.315 | 378318 | 0.40781312 | DE |
26 | -0.05 | -11.7647058824 | 0.425 | 0.475 | 0.301 | 407065 | 0.40823437 | DE |
52 | -0.6 | -61.5384615385 | 0.975 | 0.98 | 0.301 | 262070 | 0.49475402 | DE |
156 | -0.5 | -57.1428571429 | 0.875 | 1.601 | 0.301 | 283135 | 0.93635032 | DE |
260 | -0.125 | -25 | 0.5 | 1.601 | 0.301 | 391459 | 0.9080557 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.